CONTEXT: Commercial announcement of another player in the RWE dataset market | The competition for people’s data is hotting up and you can get a sense for how valuable the Continue Reading
CONTEXT: Peer reviewed article | RWR uncovering potential diagnostic bias in NASH diagnoses again illustrates the power of large data sets in real-world settings to help physicians target the best Continue Reading
CONTEXT: Peer reviewed article on RWE in multiple myeloma | Pre-publication preview IMPACT: Medium READ TIME: 1 min Quality Level Mean [1 – 10]: 4 1. “We evaluated clinical outcomes among Continue Reading
CONTEXT: Observational studies are not the same as clinical trial and yet, until recently, we had to use the same tools…and that really didn’t go well | A new Continue Reading
AUTHOR: Russell Joyce | Director & Principal Consultant | Heath Barrowcliff Consulting CONTEXT: Operational Guidance for document management for your real-world research ‘trial master file’…we prefer to call it a Continue Reading
CONTEXT: Corporate press release | It does exactly what it says on the tin. READ TIME: 2 mins Quality Level Mean [1 – 10]: 3 1. “Feb. 24, 2021 11:00 Continue Reading
CONTEXT: An opinion piece on the value of data sets in biomedical and neuroimaging studies, but only where they are compatible | When we still don’t have a common charger for Continue Reading
CONTEXT: A claim that will no doubt be tested – “Regulatory-grade evidence”. What exactly constitutes regulatory-grade RWE? Time will tell as we move into a new era for RWR | Continue Reading
CONTEXT: A study title that may slip through unnoticed as it does not explicitly mention RWR, but an interesting study showing how RWE can inform physicians on the impact of Continue Reading
Speculative article on decentralised trials in the COVID era. Will they be here to stay or will the industry revert to pulling patients in for regular visits once we are Continue Reading
